BCL2 and breast cancer: It has been observed that co-treatment of 13 and CDDP improved the sensitivity of breast cancer cells to CDDP through up-regulation of caspases 3 and 9, down-regulation of the expression of the Bcl-2 protein, increasing CDDP-induced DNA damage while reducing the level of cellular Proliferating Cell Nuclear Antigen [76].